La terapia anticoagulante nel paziente con miocardiopatia dilatativa

Translated title of the contribution: Anticoagulant treatment in patients with dilated cardiomyopathy

G. F. Gensini, C. Rostagno

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Heart failure due to dilated cardiomyopathy is associated with a significant increase in risk of thromboembolism. The incidence can be estimated, on the average, at 2.0-2.5 events per 100 patients per year. At this time, in the absence of randomized trials, limited evidence exists to support the use of anticoagulant treatment for patients with heart failure due to dilated cardiomyopathy in sinus rhythm, even if these subjects appear to be at higher risk than those with ischemic cardiomyopathy and comparable degree of left ventricular dysfunction. Women with left ventricular ejection fraction

Original languageItalian
Pages (from-to)227-232
Number of pages6
JournalAnnali Italiani di Medicina Interna
Volume13
Issue number4
Publication statusPublished - 1998

Fingerprint

Dilated Cardiomyopathy
Anticoagulants
Heart Failure
Thromboembolism
Left Ventricular Dysfunction
Cardiomyopathies
Stroke Volume
Incidence
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

La terapia anticoagulante nel paziente con miocardiopatia dilatativa. / Gensini, G. F.; Rostagno, C.

In: Annali Italiani di Medicina Interna, Vol. 13, No. 4, 1998, p. 227-232.

Research output: Contribution to journalArticle

Gensini, G. F. ; Rostagno, C. / La terapia anticoagulante nel paziente con miocardiopatia dilatativa. In: Annali Italiani di Medicina Interna. 1998 ; Vol. 13, No. 4. pp. 227-232.
@article{45092bc19a1b40429c672207546ddc26,
title = "La terapia anticoagulante nel paziente con miocardiopatia dilatativa",
abstract = "Heart failure due to dilated cardiomyopathy is associated with a significant increase in risk of thromboembolism. The incidence can be estimated, on the average, at 2.0-2.5 events per 100 patients per year. At this time, in the absence of randomized trials, limited evidence exists to support the use of anticoagulant treatment for patients with heart failure due to dilated cardiomyopathy in sinus rhythm, even if these subjects appear to be at higher risk than those with ischemic cardiomyopathy and comparable degree of left ventricular dysfunction. Women with left ventricular ejection fraction",
author = "Gensini, {G. F.} and C. Rostagno",
year = "1998",
language = "Italian",
volume = "13",
pages = "227--232",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",
number = "4",

}

TY - JOUR

T1 - La terapia anticoagulante nel paziente con miocardiopatia dilatativa

AU - Gensini, G. F.

AU - Rostagno, C.

PY - 1998

Y1 - 1998

N2 - Heart failure due to dilated cardiomyopathy is associated with a significant increase in risk of thromboembolism. The incidence can be estimated, on the average, at 2.0-2.5 events per 100 patients per year. At this time, in the absence of randomized trials, limited evidence exists to support the use of anticoagulant treatment for patients with heart failure due to dilated cardiomyopathy in sinus rhythm, even if these subjects appear to be at higher risk than those with ischemic cardiomyopathy and comparable degree of left ventricular dysfunction. Women with left ventricular ejection fraction

AB - Heart failure due to dilated cardiomyopathy is associated with a significant increase in risk of thromboembolism. The incidence can be estimated, on the average, at 2.0-2.5 events per 100 patients per year. At this time, in the absence of randomized trials, limited evidence exists to support the use of anticoagulant treatment for patients with heart failure due to dilated cardiomyopathy in sinus rhythm, even if these subjects appear to be at higher risk than those with ischemic cardiomyopathy and comparable degree of left ventricular dysfunction. Women with left ventricular ejection fraction

UR - http://www.scopus.com/inward/record.url?scp=0032423122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032423122&partnerID=8YFLogxK

M3 - Articolo

C2 - 10349204

AN - SCOPUS:0032423122

VL - 13

SP - 227

EP - 232

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

IS - 4

ER -